Groundbreaking study aims to speed up ALS treatment development
NCT ID NCT03912987
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study enrolls people with ALS and related disorders, as well as healthy volunteers, to track biological markers (biomarkers) in urine, blood, and spinal fluid. The goal is to better understand how these markers change over time, which could help design more effective future clinical trials. No experimental treatment is given; participants simply provide samples and clinical data.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALS-FRONTOTEMPORAL DEMENTIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Kansas
Kansas City, Kansas, 66160, United States
-
University of Miami
Miami, Florida, 33136, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19107, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new rowing seat help veterans with paralysis row freely?
- Can filtering the blood slow ALS in patients with a rogue antibody?
- Can sound waves soothe Dementia's emotional turmoil?
- Brain scan tracer could reveal hidden signs of psychosis in Parkinson's
- Custom-Made genetic drug takes aim at rare form of ALS
- Tailored genetic drug takes aim at a rare form of ALS